Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder.

Dialogues in clinical neuroscience - 1 Dec 2014

Leuchter Andrew F, Hunter Aimee M, Krantz David E, Cook Ian A

Abstract excerpt

Major depressive disorder (MDD) is a pleomorphic illness originating from gene x environment interactions. Patients with differing symptom phenotypes receive the same diagnosis and similar treatment recommendations without regard to genomics, brain structure or function, or other physiologic or psychosocial factors. Using this present approach, only one third of patients enter remission with the first medication...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Biomarkers
Share to Depressive Disorder, Major

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mental Health Research Topics

Share to Phenotype

Share to Treatment of Major Depression

Share to Treatment Outcome

Share to Tryptophan and brain disorders

Source

Open in PubMed Open full text

Identifiers

PMID: 25733956
PMCID: PMC4336921

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder.PMID 25733956Read ↗

Are there meaningful biomarkers of treatment response for depression?Semantic proximity Read ↗

Advancing Depression Management Through Biomarker Discovery with a Focus on Genetic and Epigenetic Aspects: A Comprehensive Study on Neurobiological, Neuroendocrine, Metabolic, and Inflammatory PathwaysSemantic proximity Read ↗

Molecular Characterization of Depression Trait and StateSemantic proximity Read ↗

Advances in biomarkers of major depressive disorder.Semantic proximity Read ↗

Genetic factors and symptom dimensions associated with antidepressant treatment outcomes: clues for new potential therapeutic targets?Semantic proximity Read ↗

Personalized medicine in major depressive disorder -- opportunities and pitfalls.Semantic proximity Read ↗

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant responseSemantic proximity Read ↗

Neurogenetics of depression: a focus on reward processing and stress sensitivity.Semantic proximity Read ↗

Dissection of the clinical phenome of major depressive disorder into subdomains and subgroups in relation to activated immune-inflammatory profilesSemantic proximity Read ↗

A review of new insights into existing major depressive disorder biomarkersSemantic proximity Read ↗

Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment.Semantic proximity Read ↗

Individualized Treatment Strategy for Depressive Disorder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.